Valuation: PT Phapros Tbk

Market Cap 235B 13.14M 11.68M 10.9M 9.93M 18.73M 1.26B 18.91M 132M 51.11M 646M 49.34M 48.27M 2.07B P/E 2024
-0.95x
P/E 2025 8.99x
Enterprise Value 821B 45.87M 40.75M 38.04M 34.67M 65.38M 4.41B 65.99M 460M 178M 2.25B 172M 168M 7.23B EV / Sales 2024
1.24x
EV / Sales 2025 0.89x
Free-Float
26.8%
Yield 2024 *
-
Yield 2025 1.67%
1 day-0.71%
1 week-2.78%
Current month-2.10%
1 month-9.09%
3 months+18.64%
6 months-8.50%
Current year-6.67%
1 week 278
Extreme 278
298
1 month 278
Extreme 278
370
Current year 206
Extreme 206
460
1 year 206
Extreme 206
460
3 years 206
Extreme 206
1,000
5 years 206
Extreme 206
1,335
10 years 206
Extreme 206
3,650
Manager TitleAgeSince
Chief Executive Officer 51 2024-06-13
Director of Finance/CFO 51 2023-12-13
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 71 2008-03-31
Director/Board Member 53 2021-05-26
Director/Board Member 49 2022-05-24
Change 5-day change 1-year change 3-year change Capi.($)
-0.71%-2.78%-14.63%-56.59% 13.14M
-0.61%-3.43%+36.07%+115.04% 1,019B
-1.02%-5.60%+35.72%+64.63% 617B
+1.11%-0.58%+12.36%+77.95% 464B
+0.34%-3.01%+61.79%+41.24% 356B
-0.95%-4.05%+20.54%+41.71% 333B
-1.46%-2.89%+10.57%+32.81% 267B
-1.35%-5.43%-6.17%+8.98% 244B
-1.04%-2.79%+35.30%+51.84% 218B
-1.87%-4.10%+28.44%+93.66% 179B
Average -0.76%-3.60%+22.00%+47.13% 369.72B
Weighted average by Cap. -0.60%-3.54%+29.07%+70.57%

Financials

2024 2025
Net sales 745B 41.61M 36.97M 34.51M 31.45M 59.32M 4B 59.87M 418M 162M 2.04B 156M 153M 6.56B 941B 52.57M 46.71M 43.6M 39.74M 74.94M 5.05B 75.64M 528M 204M 2.58B 197M 193M 8.29B
Net income -285B -15.93M -14.15M -13.21M -12.04M -22.71M -1.53B -22.92M -160M -61.94M -783M -59.8M -58.5M -2.51B 28.03B 1.57M 1.39M 1.3M 1.18M 2.23M 151M 2.25M 15.72M 6.09M 76.97M 5.88M 5.75M 247M
Net Debt 654B 36.56M 32.48M 30.32M 27.63M 52.12M 3.51B 52.6M 367M 142M 1.8B 137M 134M 5.77B 586B 32.73M 29.08M 27.14M 24.74M 46.65M 3.15B 47.08M 328M 127M 1.61B 123M 120M 5.16B
Logo PT Phapros Tbk
PT Phapros Tbk is an Indonesia-based pharmaceutical company. The Company’s segments include OTC (Over the Counter), Ethical, OGB (generic drugs bearing) and Toll-in. Its OTC segment handles over-the-counter medicinal products. Its OTC products, apart from being sold in pharmacies, can be sold through grocery stores, stalls, or minimarts. Its OGB segment handles branded generic products (OGB) and the target market for this product is government institutions and hospitals. Its Ethical segment handles products sold by prescription and the target market for the ethical division is mainly hospitals and pharmacies in addition to other health institutions. Its Toll-in manufacturing segment handles requests for drug production orders from other pharmaceutical industries. The Company's medical devices include ACS MB Primary, ACS FB and FB PS, Primary Hip Stem, INASHUNT Semilunar Flushing, BoneFill Ortho, and NPC-STRIP G. It also operates a calibration laboratory.
Employees
1,255
Date Price Change Volume
26-10-02 IDR 280.00 -0.71% 259,600
26-10-01 IDR 282.00 -1.40% 142,000
26-09-30 IDR 286.00 +0.70% 261,700
26-09-29 IDR 284.00 -2.74% 331,200
26-09-28 IDR 292.00 +1.39% 338,500
  1. Stock Market
  2. Stocks
  3. PEHA Stock